Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Markman

Showing results (341-350 of 545) with videos related to

Pageof 55
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2001
Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneumM Markman, A Kennedy, K Webster, et al.
JACC. Clinical Electrophysiology|July 30, 2022
Feasibility of Computed Tomography-Guided Cardioneuroablation for Atrial FibrillationTimothy M Markman, Mirmilad Khoshknab, Pasquale Santangeli, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1997
Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesisM Markman, A Kennedy, K Webster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer CenterM Markman, A Kennedy, K Webster, et al.
Journal of Cancer Research and Clinical Oncology|February 24, 2001
Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignanciesM Markman, A Kennedy, K Webster, et al.
Gynecologic Oncology|March 1, 1996
Control of carboplatin-induced emesis with a fixed low dose of granisetron (0.5 mg) plus dexamethasoneM Markman, A Kennedy, K Webster, et al.
Seminars in Oncology|June 1, 1996
Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitisM Markman, A Kennedy, K Webster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1995
Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot StudyP Francis, E Rowinsky, J Schneider, et al.
Gynecologic Oncology|September 23, 1997
Leuprolide in the treatment of endometrial cancerM Markman, A Kennedy, K Webster, et al.
Journal of Cancer Research and Clinical Oncology|August 6, 1998
Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinomaM Markman, A Kennedy, K Webster, et al.
Pageof 55

Showing results (341-350 of 545) with videos related to

Sort By:
Pageof 55
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2001
Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneumM Markman, A Kennedy, K Webster, et al.
JACC. Clinical Electrophysiology|July 30, 2022
Feasibility of Computed Tomography-Guided Cardioneuroablation for Atrial FibrillationTimothy M Markman, Mirmilad Khoshknab, Pasquale Santangeli, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1997
Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesisM Markman, A Kennedy, K Webster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer CenterM Markman, A Kennedy, K Webster, et al.
Journal of Cancer Research and Clinical Oncology|February 24, 2001
Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignanciesM Markman, A Kennedy, K Webster, et al.
Gynecologic Oncology|March 1, 1996
Control of carboplatin-induced emesis with a fixed low dose of granisetron (0.5 mg) plus dexamethasoneM Markman, A Kennedy, K Webster, et al.
Seminars in Oncology|June 1, 1996
Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitisM Markman, A Kennedy, K Webster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1995
Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot StudyP Francis, E Rowinsky, J Schneider, et al.
Gynecologic Oncology|September 23, 1997
Leuprolide in the treatment of endometrial cancerM Markman, A Kennedy, K Webster, et al.
Journal of Cancer Research and Clinical Oncology|August 6, 1998
Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinomaM Markman, A Kennedy, K Webster, et al.
Pageof 55